NASP Submits Comments on Proposed Regulations for Global Benchmark for Efficient Drug Pricing (GLOBE) Model; Proposed Rule (90 FR 60244)

In comments on CMS’s proposed Global Benchmark for Efficient Drug Pricing (GLOBE) Model, NASP urged revisions to the international reference pricing framework for Medicare Part B drugs, warning it could destabilize specialty pharmacy operations and threaten patient access. Click here to read the full comments.